Trial Profile
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Efavirenz; Lamivudine/abacavir; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUPPoRT
- 15 Oct 2011 Results presented at the 13th European AIDS Conference.
- 14 Oct 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.